Reduced blood platelet sensitivity to aspirin in coronary artery disease: Are dyslipidaemia and inflammatory states possible factors predisposing to sub-optimal platelet response to aspirin?

Basic and Clinical Pharmacology and Toxicology

Volumn 98, Issue 5, 2006, Pages 503-509

  Markuszewski, Leszek ^a   Rosiak, Marcin ^a   Golanski, Jacek ^a   Rysz, Jacek ^a   Spychalska, Magdalena ^a   Watala, Cezary ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; ACETYLSALICYLIC ACID; ARACHIDONIC ACID; C REACTIVE PROTEIN; COLLAGEN; CREATININE; THROMBOXANE; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHRONIC INFLAMMATION; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG RESPONSE; DRUG SENSITIVITY; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; THROMBOCYTE; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; TURBIDIMETRY; URINALYSIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; BLOOD PLATELETS; C-REACTIVE PROTEIN; CHOLESTEROL; CORONARY ARTERIOSCLEROSIS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; INFLAMMATION; MALE; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; THROMBOXANE B2; TRIGLYCERIDES;

EID: 33646238447     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2006.pto_343.x     Document Type: Article

References (37)

1. Altman R. H. L. Luciardi J. Muntaner R. N. Herrera The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb. J. 2004 2
2. Armitage P. G. Berry J. N. S. Matthews Statistical methods in medical research 2002 4th ed. Blackwell Oxford pp. 1 817
3. Benedito M. A. Fluorimetric determination of tissue distribution and differences between the activity of aspirin esterases I and II in mice and rats J. Pharm. Pharmacol. 1997 49 273 276
4. Boncler M. A. J. Golanski R. Paczuski C. Watala Polymorphisms of glycoprotein Ib affect the inhibition by aurintricarboxylic acid of the von Willebrand factor dependent platelet aggregation J. Mol. Med. 2002 80 796 801
5. Cambria-Kiely J. A. P. J. Gandhi Aspirin resistance and genetic polymorphisms J. Thromb. Thrombolysis 2002a 14 51 58
6. Cambria-Kiely J. A. P. J. Gandhi Possible mechanisms of aspirin resistance J. Thromb. Thrombolysis 2002b 13 49 56
7. Carroll R. C. R. M. Craft J. J. Chavez C. C. Snider S. J. Bresee E. Cohen A thrombelastograph whole blood assay for clinical monitoring of NSAID-insensitive transcellular platelet activation by arachidonic acid J. Lab Clin. Med. 2005 146 30 35
8. Coma-Canella I. A. Velasco S. Castano Prevalence of aspirin resistance measured by PFA-100 Int. J. Cardiol. 2005 101 71 76
9. Crowe B. S. Abbas B. Meany J. de Haan M. R. Cahill Detection of aspirin resistance by PFA-100: prevalence and aspirin compliance in patients with chronic stable angina Semin. Thromb. Hemost. 2005 31 420 425
10. Drzewoski J. C. Watala Is aspirin resistance a real problem in people with type 2 diabetes? Diabetes Care 2004 27 1245 1246
11. Eikelboom J. W. J. Hirsh J. I. Weitz M. Johnston Q. Yi S. Yusuf Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events Circulation 2002 105 1650 1655
12. Esmon C. T. Inflammation and thrombosis J. Thromb. Haemost. 2003 1 1343 1348
13. Friend M. I. Vucenik M. Miller Research pointers: Platelet responsiveness to aspirin in patients with hyperlipidaemia Brit. Med. J. 2003 326 82 83
14. Golanski J. S. Chlopicki R. Golanski P. Gresner A. Iwaszkiewicz C. Watala Resistance to aspirin in patients after coronary artery bypass grafting is transient: impact on the monitoring of aspirin antiplatelet therapy Therap. Drug Monit. 2005 27 484 490
15. Gum P. A. K. Kottke-Marchant E. D. Poggio H. Gurm P. A. Welsh L. Brooks S. K. Sapp E. J. Topol Profile and prevalence of aspirin resistance in patients with cardiovascular disease Amer. J. Cardiol. 2001 88 230 235
16. Haubelt H. C. Anders P. Hellstern Can platelet function tests predict the clinical efficacy of aspirin? Semin. Thromb. Hemost. 2005 31 404 410
17. Helgason C. M. K. L. Tortorice S. R. Winkler D. W. Penney J. J. Schuler T. J. McClelland L. D. Brace Aspirin response and failure in cerebral infarction Stroke 1993 24 345 350
18. Howard P. A. Aspirin resistance Ann. Pharmacother. 2002 36 1620 1624
19. Jilma B. I. Fuchs Aspirin. Methods to assess aspirin resistance J. Thromb. Haemost. 2004 2 337 338
20. Lellouche F. A. Fradin G. Fitzgerald J. Maclouf Enzyme immunoassay measurement of the urinary metabolites of thromboxane A2 and prostacyclin Prostaglandins 1990 40 297 310
21. Macchi L. L. Christiaens S. Brabant N. Sorel J. Allal G. Mauco A. Brizard Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate Thromb. Res. 2002 107 45 49
22. Manolis A. S. S. Tzeis G. Andrikopoulos S. Koulouris H. Melita Aspirin and clopidogrel: a sweeping combination in cardiology Curr. Med. Chem. Cardiovasc. Hematol. Agents 2005 3 203 219
23. Maree A. O. R. J. Curtin M. Dooley R. M. Conroy P. Crean D. Cox D. J. Fitzgerald Platelet response to low-dose enteric-coated aspirin in patients with stable cardiovascular disease J. Amer. Coll. Cardiol. 2005 46 1258 1263
24. Mason P. J. J. E. Freedman A. K. Jacobs Aspirin resistance: current concepts Rev. Cardiovasc. Med. 2004 5 156 163
25. Mason P. J. A. K. Jacobs J. E. Freedman Aspirin resistance and atherothrombotic disease J. Amer. Coll. Cardiol. 2005 46 986 993
26. Matzdorff A. Platelet function tests and flow cytometry to monitor antiplatelet therapy Semin. Thromb. Hemost. 2005 31 393 399
27. Michelson A. D. M. Cattaneo J. W. Eikelboom P. Gurbel K. Kottke-Marchant T. J. Kunicki F. M. Pulcinelli C. Cerletti A. K. Rao Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis; Working Group on Aspirin Resistance: Aspirin resistance: position paper of the Working Group on Aspirin Resistance J. Thromb. Haemost. 2005 3 1309 1311
28. Murphy R. C. G. A. FitzGerald Current approaches to estimation of eicosanoid formation in vivo Adv. Prostaglandin Thromboxane Leukot. Res. 1994 22 341 348
29. Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs J. Thromb. Haemost. 2003 1 1710 1713
30. Pettersen A. A. I. Seljeflot M. Abdelnoor H. Arnesen Unstable angina, stroke, myocardial infarction and death in aspirin non-responders. A prospective, randomized trial. The ASCET (ASpirin non-responsiveness and Clopidogrel Endpoint Trial) design Scand. Cardiovasc. J. 2004 38 353 356
31. Rozalski M. M. Boncler J. Golanski C. Watala Effects of fibrinogen receptor antagonist GR144053F and aurintricarboxylic acid on platelet activation and degranulation Biochem. Pharmacol. 2001 62 1399 1408
32. Sambola A. M. Heras G. Escolar M. Lozano M. Pino T. Martorell M. Torra G. Sanz The PFA-100 detects sub-optimal antiplatelet responses in patients on aspirin Platelets 2004 15 439 446
33. Sztriha L. K. K. Sas L. Vecsei Aspirin resistance in stroke: 2004 J. Neurol. Sci. 2005 229-230 163 169
34. Watala C. J. Golanski J. Pluta M. Boncler M. Rozalski B. Luzak A. Kropiwnicka J. Drzewoski Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control Thromb. Res. 2004 113 101 113
35. Watala C. J. Golanski M. Rozalski M. A. Boncler B. Luzak J. Baraniak D. Korczynski W. Drygas Is platelet aggregation a more important contributor than platelet adhesion to the overall platelet-related primary haemostasis measured by PFA-100? Thromb. Res. 2003 109 299 306
36. Weber A. A. B. Przytulski A. Schanz T. Hohlfeld K. Schror Towards a definition of aspirin resistance: a typological approach Platelets 2002 13 37 40
37. Zar J. Biostatistical analysis Simon & Schuster/A Viacom Company Upper Saddle River, NJ, Prentice-Hall International, Inc. 2004 4th ed. pp. 1 663